news
Laurel V. Williams
The Ministry of Health, through the Chemical, Food and Drug Administration, said an India-based manufacturer had recalled 114 batches of the capsules due to fears they could cause cardiac arrest.
The ministry said in a July 4 statement that Glenmark Pharmaceuticals Inc. had voluntarily recalled a lot of Potassium Chloride Extended-Release Capsules, USP (750 mg) 10 mEq K, due to poor dissolution.
This medication is used to treat people with low potassium levels (hypokalemia).
The failed medication is packaged in bottles of 100 (NDC 68462-357-01) and 500 (NDC 68462-357-05) capsules.
“Failure of potassium chloride extended-release capsules to dissolve can cause high potassium levels, also known as hyperkalemia, which can lead to irregular heart rhythms and potentially cardiac arrest,” the statement said.
The recalled products are not registered for use in Trinidad and Tobago.
However, out of an abundance of caution, the department said it is advising anyone who may have the recalled products to immediately stop using them and, if possible, return them to the place of purchase.”
The ministry also provided a table listing batch numbers and expiry dates ranging from June 2024 to September 2025.
The agency said it would continue to monitor the situation and advise the public as necessary.
For more information, call 217-4664 extension 13101 or email [email protected].
